Pfizer Colorectal Cancer Trial Win Adds Weight To Oncology Turnaround Story
Pfizer (NYSE:PFE) reported positive topline results from its pivotal BREAKWATER trial. The study evaluated a BRAFTOVI based combination in previously untreated metastatic colorectal cancer with a BRAF V600E mutation. Results showed a clinically meaningful improvement in progression free survival for patients in the first line setting. The update reflects progress toward a potential new regulatory filing for this col…
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
